AQP4 (201-220) TFA
Based on 1 Customer Validation
AQP4 (201-220) TFA is an encephalitogenic epitope of AQP-4. AQP4 (201-220) TFA can induce experimental autoimmune encephalomyelitis (EAE) (characterized by midline lesions in the brain, retinal pathology, and lesions at the grey matter/white matter border zone in the spinal cord). AQP-4 is a target antigen in neuromyelitis optica.
For research use only. We do not sell to patients.
- Purity: 99.91%
- Formula: C97H143N27O27S·xC2HF3O2
- Molecular Weight:2151.40 (free acid)
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.
AQP4 (201-220) TFA can be used to induce experimental autoimmune encephalomyelitis (EAE) models[1][2][3][4].
Administration: AQP4 (201-220) 200 μg • s.c. (the base of the mouse's tail) • single dose
(2) At the same time as the administration, pertussis toxin (200 ng per mouse) is injected intravenously, and another dose is given on the second day.
Histological analysis: Scattered or focal inflammatory lesions appear in the gray-white matter junction area; inflammatory lesions appear in the diencephalic midline area (near the third ventricle) and around the fourth ventricle; inflammatory infiltration appears in the inner layer of the retina, accompanied by loss of retinal ganglion cells.
Cellular analysis: Significant infiltration of CD45+ immune cells and CD4+ T cells in the CNS (brain, spinal cord, retina), and an increase in the number of Iba-1 and GAFP positive cells in the lesion area.
Molecular changes: Decreased expression of AQP4; increased expression of IFN-γ, IL-17, CXCL10, and CCL20.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Appearance Solid
-
Molecular Weight 2151.40 (free acid)
-
Formula C97H143N27O27S·xC2HF3O2
-
Color White to off-white
-
Sequence
His-Leu-Phe-Ala-Ile-Asn-Tyr-Thr-Gly-Ala-Ser-Met-Asn-Pro-Ala-Arg-Ser-Phe-Gly-Pro
-
Sequence Shortening
HLFAINYTGASMNPARSFGP
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 100 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 50 mg/mL (Need ultrasonic)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL; Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL; Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Afzali AM, et al. AQP4-specific T cells determine lesion localization in the CNS in a model of NMOSD. Acta Neuropathol Commun. 2025 Feb 11;13(1):27. [Content Brief]
[3]. Afzali AM, et al. B cells orchestrate tolerance to the neuromyelitis optica autoantigen AQP4. Nature. 2024 Mar;627(8003):407-415. [Content Brief]
[4]. Arellano G, et al. Interferon-γ controls aquaporin 4-specific Th17 and B cells in neuromyelitis optica spectrum disorder. Brain. 2024 Apr 4;147(4):1344-1361. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
AQP4 (201-220) TFA Related Classifications
HY-P10936A Related Classifications
Powered by Bioz